Amphastar Pharmaceuticals Inc CFO, EVP & Treasurer William Peters Sells 18,136 Shares
William Peters, the Chief Financial Officer, Executive Vice President, and Treasurer of Amphastar Pharmaceuticals Inc (NASDAQ:AMPH), has sold 18,136 shares of the company on March 6, 2024, according to a recent SEC filing. The transaction was executed at an average price of $46.48 per share, resulting in a total value of $843,529.28.
Amphastar Pharmaceuticals Inc is a biopharmaceutical company that focuses on the development, manufacturing, and marketing of proprietary and generic injectable and inhalation products. These products are used in hospitals and ambulatory surgery centers, as well as in the treatment of diabetes and other conditions.
Over the past year, William Peters has sold a total of 192,937 shares of Amphastar Pharmaceuticals Inc and has not made any purchases of the stock. The insider transaction history for the company shows a pattern of insider selling, with 35 insider sells and no insider buys over the same timeframe.
On the valuation front, Amphastar Pharmaceuticals Inc's shares were trading at $46.48 on the day of the insider's recent sale, giving the company a market capitalization of $2.194 billion. The price-earnings ratio of the company stands at 17.70, which is lower than the industry median of 22.945 and also below the company's historical median price-earnings ratio.
According to the GuruFocus Value, with a price of $46.48 and a GF Value of $37.60, Amphastar Pharmaceuticals Inc has a price-to-GF-Value ratio of 1.24, indicating that the stock is modestly overvalued.
The GF Value is calculated considering historical trading multiples, a GuruFocus adjustment factor based on the company's past returns and growth, and future business performance estimates provided by Morningstar analysts.
The recent insider sell by William Peters may provide investors with an indication of the insider's perspective on the stock's current valuation. However, investors should also consider the broader market conditions, the company's fundamentals, and their investment strategy when evaluating this insider transaction.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
This article first appeared on GuruFocus.
